News

Developed in collaboration with the University of Oslo, Norway, Albufuse Flex technology will facilitate manipulation based on this FcRn-albumin interaction, enabling a tunable half-life that offers control and

Avandia (rosiglitazone maleate) is an oral antidiabetic agent which acts primarily by increasing insulin sensitivity. The cases were filed against GSK as studies linked the drug to increased

The novel small molecule scaffolds were identified using COTI’s drug discovery technology CHEMSAS. CHEMSAS uses a series of predictive computer models to identify compounds most likely to be

The company reported a net loss of $32.67m, or $0.3 per diluted share, compared to a net income of $11.46m, or $0.11 per diluted share, for the same

The increase in revenues was due to primarily funding from the company’s collaborative partner Les Laboratoires Servier for XOMA 052 development and increased funding under the company’s contracts

The company reported a net loss of $84.07m or $2.49 loss per diluted share, compared to a net income of $476,000 or $0.01per diluted share, for the same

The FDA approval was given on the basis of RADIANT-3 (RAD001 In Advanced Neuroendocrine Tumors) Phase III trial data which showed that treatment with Afinitor more than doubled

Both the parties have decided to fund a Phase 1 trial investigating OSI-906 as a single agent and in conjunction with the proteasome inhibitor bortezomib to treat relapsed

Biovista expects to utilize its Clinical Outcomes Search Space (COSS) platform and multi-dimensional profiling capabilities to identify new treatments that reflect patients’ individual pathophysiological characteristics. The ‘p-medicine’ project